Regional Variability in MRI Scans with Different Magnetic Field Strengths in Japan: Implications for Healthcare Preparedness for Alzheimer’s Disease Treatment

Author:

Sato Kenichiro12,Niimi Yoshiki23,Ihara Ryoko4,Iwata Atsushi4ORCID,Iwatsubo Takeshi12

Affiliation:

1. Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan

2. Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo 113-8655, Japan

3. Department of Healthcare Economics and Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan

4. Department of Neurology, Tokyo Metopolitan Institute for Geriatrics and Gerontology, Tokyo 173-0015, Japan

Abstract

(1) Background: The 2023 approval of lecanemab for early-stage Alzheimer’s disease (AD) highlighted the need for routine 1.5T or 3.0T MRI scans to monitor amyloid-related imaging abnormalities (ARIAs). Regional disparities in MRI scan frequency, MRI scanner availability, and scanner magnetic field strengths could affect readiness for anti-amyloid therapy and lead to inconsistencies in ARIA detection nationwide. (2) Methods: We assessed regional variance in MRI scan frequency and field strength across Japan using the National Database (NDB) Open Data website, which summarizes Japanese public health insurance claims from the fiscal years (FYs) 2015 to 2021. We employed a mixed-effects model with prefecture-level random intercepts and slopes over time, subsequently categorizing prefectures into clusters based on MRI usage. (3) Results: 1.5T MRI was the most common magnetic field strength, remaining stable from FY2015 to FY2021. 3.0T MRI usage slightly increased, although the COVID-19 pandemic in FY2020 led to a maximum reduction of 5%. Prefecture-level variance was higher for 3.0T MRIs, with more frequent usage in western Japan. (4) Conclusions: This study highlights prefecture-level variance in MRI usage across Japan. The insights gained could be instrumental in improving healthcare preparedness for anti-amyloid treatment and patient management.

Funder

AMED

Publisher

MDPI AG

Reference27 articles.

1. Alzheimer disease;Knopman;Nat. Rev. Dis. Primers,2021

2. Global estimates on the number of persons across the Alzheimer’s disease continuum;Gustavsson;Alzheimer’s Dement.,2023

3. Daigaku, K. (2024, July 25). Survey on about Pevalence and Future Estimates of Dementia and Mild Cognitive Impairment. (In Japanese).

4. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease;Jack;Alzheimer’s Dement.,2018

5. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer’s disease;Honig;Alzheimer’s Dement.,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3